Related Experiment Video

Updated: Feb 16, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.3K

The Alcohol-Abuse Drug Disulfiram Targets NPL4 to Exert Antitumor Effects

    Cancer Discovery
    |December 17, 2017
    PubMed

    Insights

    Disulfiram use was linked to lower cancer death rates in individuals who continued the medication for alcohol dependency. This finding suggests a potential role for disulfiram beyond alcohol treatment.

    Area of Science:

    • Oncology
    • Pharmacology
    • Addiction Medicine

    Background:

    • Disulfiram is a well-established medication for treating alcohol use disorder.
    • Emerging evidence suggests potential anticancer properties of disulfiram.
    • Further investigation is needed to understand disulfiram's impact on cancer outcomes.

    Purpose of the Study:

    • To investigate the association between disulfiram use and cancer mortality.
    • To determine if continued disulfiram treatment for alcohol dependency influences cancer survival.

    Main Methods:

    • Retrospective cohort study design.
    • Analysis of patient data including medication adherence and cancer diagnosis.
    • Statistical methods to adjust for confounding factors.

    Main Results:

    • Patients who adhered to disulfiram treatment for alcohol dependency exhibited reduced cancer mortality.
    • A significant inverse relationship was observed between disulfiram continuation and cancer-related deaths.

    Conclusions:

    • Continued disulfiram therapy for alcohol dependency may be associated with improved cancer survival.
    • Disulfiram's potential as an adjunct cancer therapy warrants further clinical investigation.

    More Related Videos

    Rapid Identification of Chemical Genetic Interactions in Saccharomyces cerevisiae12:13

    Rapid Identification of Chemical Genetic Interactions in Saccharomyces cerevisiae

    Published on: April 5, 2015

    10.8K
    Regioselective O-Glycosylation of Nucleosides via the Temporary 2',3'-Diol Protection by a Boronic Ester for the Synthesis of Disaccharide Nucleosides08:46

    Regioselective O-Glycosylation of Nucleosides via the Temporary 2',3'-Diol Protection by a Boronic Ester for the Synthesis of Disaccharide Nucleosides

    Published on: July 26, 2018

    9.2K

    Related Concept Videos

    Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

    Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

    Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
    12
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    15
    Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

    Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

    Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
    653
    Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

    Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

    5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
    718